Franchise Capital’s Moderna MRNA Stock Holding History

Franchise Capital’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-59,973	Closed	-$23.1M	–	20
2021 Q3	$23.1M	Buy	+59,973	New	+$22.1M	2.76%	14

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franchise Capital's MRNA Position: Q4 2021 in Review

Franchise Capital sold out of Moderna (MRNA) in Q4 2021, closing a stake of 59,973 shares — an estimated $23.1M sold.

Franchise Capital first reported a position in MRNA in Q3 2021 and held it in 1 quarter. The position peaked at $23.1M in Q3 2021. 1,110 funds tracked by Wall St. Rank hold MRNA as of Q4 2021.

Franchise Capital reported no remaining Moderna position as of Q4 2021 after selling out during the quarter.
Franchise Capital sold 59,973 Moderna shares in Q4 2021, an estimated $23.1M.
Franchise Capital first reported a position in Moderna in Q3 2021 and held it in 1 quarter.
Franchise Capital's Moderna position peaked at $23.1M in Q3 2021.
1,110 funds tracked by Wall St. Rank held Moderna as of Q4 2021.

Based on Franchise Capital's 13F filing for Q4 2021, filed 15 Feb 2022.